药明生物推出技术平台WuXia™ RidGS，赋能客户研发非抗生素细胞株

美通社2024-10-28

上海2024年10月28日 /美通社/ -- 全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布推出基于高产量谷氨酰胺合成酶（GS）的中国仓鼠卵巢（CHO）表达系统WuXia™ RidGS细胞株构建平台。该平台为非抗生素细胞株的研发平台，利用锌指核酸酶（ZFN）技术，敲除CHO细胞中的内源性GS基因。 WuXia™ RidGS衍生自...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2478171378?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-28 17:00","share_image_url":"https://static.laohu8.com/7d5258e5fa9d58069a293859983c0a71","id":"2478171378","market":"us","top_or_hot":-1,"title":"药明生物推出技术平台WuXia™ RidGS，赋能客户研发非抗生素细胞株","media":"美通社","content":"<div>\n<p>上海2024年10月28日 /美通社/ -- 全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布推出基于高产量谷氨酰胺合成酶（GS）的中国仓鼠卵巢（CHO）表达系统WuXia™ RidGS细胞株构建平台。该平台为非抗生素细胞株的研发平台，利用锌指核酸酶（ZFN）技术，敲除CHO细胞中的内源性GS基因。 WuXia™ RidGS衍生自...</p>\n\n<a href=\"https://wwwold.prnasia.com/story/archive/4541340_ZH41340_1\">网页链接</a>\n\n</div>\n","source":"prnasia","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>药明生物推出技术平台WuXia™ RidGS，赋能客户研发非抗生素细胞株</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n药明生物推出技术平台WuXia™ RidGS，赋能客户研发非抗生素细胞株\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-28 17:00 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wwwold.prnasia.com/story/archive/4541340_ZH41340_1><strong>美通社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>上海2024年10月28日 /美通社/ -- 全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布推出基于高产量谷氨酰胺合成酶（GS）的中国仓鼠卵巢（CHO）表达系统WuXia™ RidGS细胞株构建平台。该平台为非抗生素细胞株的研发平台，利用锌指核酸酶（ZFN）技术，敲除CHO细胞中的内源性GS基因。 WuXia™ RidGS衍生自...</p>\n\n<a href=\"https://wwwold.prnasia.com/story/archive/4541340_ZH41340_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1242518857.USD","symbol_name":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","start_time":0,"source_url":"https://wwwold.prnasia.com/story/archive/4541340_ZH41340_1","article_id":"2478171378","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478171378","pubTimestamp":1730106000,"columns":[],"sourceInfo":{"source_id":"prnasia","name":"美通社"},"weMediaInfo":null,"summary":"WuXia RidGS衍生自WuXia细胞株构建平台，并继承了WuXia强大的细胞生长、代谢和表达水平。其单克隆抗体产品的平均克隆表达水平超过6 g/L，同时，WuXia RidGS能够确保单克隆抗体、双特异性抗体、融合蛋白和重组蛋白等多种疗法类型的细胞株稳定性。值得一提的是，在不使用抗生素情况下，WuXia RidGS宿主细胞和生产细胞在长期细胞传代中，始终保持稳定的产物表达量及产品质量。在WuXia卓越特性的基础上，WuXiaADCC Plus和WuXia RidGS积极满足全球客户的多元化需求。","collect":0,"end_time":0,"defaultTopTitle":"prnasia.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","WXXWY":"药明生物ADR","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","02269":"药明生物","LU0823426480.USD":"法巴中国股票经典Dis","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU1791807156.HKD":"BGF WORLD FINANCIALS \"A2\" (HKDHDG) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","BK4121":"生命科学工具和服务","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","ESG":"FlexShares STOXX US ESG Select Index Fund","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4585":"ETF&股票定投概念","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","BK1141":"生命科学工具和服务","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1576":"医药外包概念","LU0106831901.USD":"贝莱德世界金融基金A2","BK4504":"桥水持仓","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","BK4550":"红杉资本持仓"},"translate_title":"WuXi Biologics launches technology platform WuXia ™ RidGS to empower customers to develop non-antibiotic cell lines","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WXXWY":0.9,"02269":1,"ESG":1},"content_text":"上海2024年10月28日 /美通社/ -- 全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布推出基于高产量谷氨酰胺合成酶（GS）的中国仓鼠卵巢（CHO）表达系统WuXia™ RidGS细胞株构建平台。该平台为非抗生素细胞株的研发平台，利用锌指核酸酶（ZFN）技术，敲除CHO细胞中的内源性GS基因。 WuXia™ RidGS衍生自WuXia™细胞株构建平台，并继承了WuXia™强大的细胞生长、代谢和表达水平。其单克隆抗体产品的平均克隆表达水平超过6 g/L，同时，WuXia™ RidGS能够确保单克隆抗体、双特异性抗体、融合蛋白和重组蛋白等多种疗法类型的细胞株稳定性。此外，该技术平台所表达的蛋白产品质量拥有良好的糖基化修饰水平，同时保持了极高的纯度。值得一提的是，在不使用抗生素情况下，WuXia™ RidGS宿主细胞和生产细胞在长期细胞传代中，始终保持稳定的产物表达量及产品质量。 药明生物首席执行官陈智胜博士表示：\"我们很高兴推出WuXia™ RidGS技术平台，为先进的治疗性蛋白产品的开发提供更高效的解决方案。为满足全球客户的多元化需求，药明生物矢志不渝地构建定制化的自主研发技术平台。我们赋能全球合作伙伴，加快创新药的研发，让全球患者能够用上更多、更具有可及性的高质量生物药。\" 关于WuXia™细胞株构建系列平台 WuXia™是药明生物开发的高产哺乳动物细胞株构建平台，产量最高达11g/L。该技术平台已获得全球药品监管机构的认可，开发了超过900个表达单克隆抗体、双特异性抗体、融合蛋白、酶和其他重组蛋白的细胞株，用于临床和商业化生产。在WuXia™卓越特性的基础上，WuXiaADCC Plus™和WuXia™ RidGS积极满足全球客户的多元化需求。 关于药明生物 药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。 药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2024年6月底，药明生物帮助客户研发和生产的综合项目高达742个，其中包括16个商业化生产项目（不包括新冠项目和非活跃项目）。 药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。更多信息，请访问：","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478171378","isCrawlerRequest":true}